医学                        
                
                                
                        
                            索拉非尼                        
                
                                
                        
                            肝细胞癌                        
                
                                
                        
                            卡波扎尼布                        
                
                                
                        
                            内科学                        
                
                                
                        
                            实体瘤疗效评价标准                        
                
                                
                        
                            肿瘤科                        
                
                                
                        
                            阿替唑单抗                        
                
                                
                        
                            肝功能                        
                
                                
                        
                            癌                        
                
                                
                        
                            癌症                        
                
                                
                        
                            临床研究阶段                        
                
                                
                        
                            临床试验                        
                
                                
                        
                            胃肠病学                        
                
                                
                        
                            外科                        
                
                                
                        
                            彭布罗利珠单抗                        
                
                                
                        
                            免疫疗法                        
                
                        
                    
            作者
            
                Robin Kate Kelley,Lorenza Rimassa,Ann‐Lii Cheng,Ahmed O. Kaseb,Shukui Qin,Andrew X. Zhu,Stephen L. Chan,Tamar Melkadze,Wattana Sukeepaisarnjaroen,В. В. Бредер,Gontran Verset,Edward Gane,Ivan Borbath,Jose David Gomez Rangel,Baek‐Yeol Ryoo,Tamta Makharadze,Philippe Merle,Fawzi Benzaghou,Kamalika Banerjee,Saswati Hazra            
         
                    
            出处
            
                                    期刊:Lancet Oncology
                                                         [Elsevier BV]
                                                        日期:2022-07-04
                                                        卷期号:23 (8): 995-1008
                                                        被引量:445
                                 
         
        
    
            
            标识
            
                                    DOI:10.1016/s1470-2045(22)00326-6
                                    
                                
                                 
         
        
                
            摘要
            
            Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma.
         
            
 
                 
                
                    
                    科研通智能强力驱动
Strongly Powered by AbleSci AI